Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease by Orth, M et al.
For Peer Review
 
 
 
 
 
 
Natural variation in sensory-motor white matter 
organization influences manifestations of Huntington’s 
Disease 
 
 
Journal: Human Brain Mapping 
Manuscript ID HBM-16-0290.R2 
Wiley - Manuscript type: Research Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Orth, Michael; University of Ulm, Department of Neurology 
Gregory, Sarah; Wellcome Trust Centre for Neuroimaging,  
Scahill, Rachael; University College London, Institute of Neurology 
Mayer, Isabella; University of Ulm, Department of Neurology 
Minkova, Lora; University Medical Center Freiburg, Freiburg Brain Imaging 
Kloeppel, Stefan; University of Freiburg 
Seunarine, Kiran; UCL Institute of Child Health, Imaging and Biophysics 
Unit 
Boyd, Lara; University of British Columbia,  
Borowsky, Beth; CHDI Foundation Inc 
Reilmann, Ralf; George-Huntington-Institute 
Landwehrmeyer, Bernhard; University of Ulm, Neurology 
Leavitt, Blair; University of British Columbia, Department of Medical 
Genetics 
Roos, Raymund; Leiden University Medical Centre, Neurology 
Durr, Alexandra; Universite Pierre et Marie Curie, Paris, Department of 
Genetics and Cytogenetics 
Rees, Geraint; UCL Institute of Cognitive Neuroscience,  
Rothwell, John; University College London Institute of Neurology 
Langbehn, Douglas; University of Iowa, Departments of Psychiatry and 
Biostatistics 
Tabrizi, Sarah; University College London, Institute of Neurology 
Keywords: 
effective connectivity, cortical thickness, SEP, grip force, principal 
component analysis, biological trait 
  
 
 
John Wiley & Sons, Inc.
Human Brain Mapping
For Peer Review
1 
 
Natural variation in sensory-motor white matter organization influences manifestations of 
Huntington’s Disease 
Michael Orth MD
1
, Sarah Gregory PhD
2
, Rachael I Scahill PhD
3
, Isabella SM Mayer RA
1,4
, Lora Minkova 
PhD
5
, Stefan Klöppel MD
6
, Kiran K Seunarine PhD
7
, Lara Boyd PhD
8
, Beth Borowsky PhD
9
, Ralf 
Reilmann MD
10
, G. Bernhard Landwehrmeyer MD, Blair R Leavitt MD
11
, Raymund AC Roos MD
12
, 
Alexandra Durr MD
13
, Geraint Rees PhD
2
, John C Rothwell PhD
4
, Douglas Langbehn MD
14
, Sarah J 
Tabrizi MD
15
, and the TRACK-On Investigators s  
1
Department of Neurology, Ulm University Hospital, Ulm, Germany 
2
Wellcome Trust Centre for Neuroimaging, University College London, London, UK  
3
HD Research Group, UCL Institute of Neurology, Queen Square, London, UK 
4
Sobell Department of Motor Neuroscience and Movement Disorders, University College London 
Institute of Neurology, Queen Square, London, UK 
5
Department of Psychiatry and Psychotherapy; Freiburg Brain Imaging, University Medical Center, 
Albert-Ludwigs-University Freiburg, Freiburg, Germany  
6
Department of Psychiatry and Psychotherapy; Department of Neurology; Freiburg Brain Imaging, 
University Medical Center, Albert-Ludwigs-University Freiburg, Freiburg, Germany 
7
Developmental Imaging and Biophysics Section, UCL Institute of Child Health, London, UK 
8
Centre for Brain Health, University of British Columbia, Vancouver, Canada 
9
CHDI Foundation Inc., Princeton, NJ, USA 
10
George-Huntington-Institute, Technology-Park Muenster, Muenster, Germany 
11
Center for Molecular Medicine and Therapeutics and Department of Medical Genetics, Child and 
Family Research Institute, University of British Columbia, Vancouver, Canada 
12
Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands 
Page 1 of 40
John Wiley & Sons, Inc.
Human Brain Mapping
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
13
APHP Department of Genetics, Groupe Hospitalier Pitié-Salpêtrière, and Institut du Cerveau et de la 
Moelle, INSERM U1127, CNRS UMR7225, UPMC Université Paris VI UMR_S1127, Paris France 
14
Departments of Psychiatry and Biostatistics, University of Iowa, Iowa City, IA, USA 
15
Department of Neurodegenerative Disease, University College London, Institute of Neurology, 
Queen Square, London, UK 
 
Contact for correspondence 
Michael Orth, M.D., Ph.D. 
Department of Neurology, Ulm University Hospital 
Oberer Eselsberg 45/1 
89081 Ulm, Germany 
e-mail: michael.orth@uni-ulm.de; Tel: +49-731 50063095; Fax: +49-731 50063082 
 
Running head: Natural variation influences HD manifestations 
 
Keywords: effective connectivity; cortical thickness; somatosensory evoked potentials; grip force; 
principal component analysis; biological variation; biological trait 
 
 
 
 
 
 
 
Page 2 of 40
John Wiley & Sons, Inc.
Human Brain Mapping
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
 
Abstract 
While the HTT CAG-repeat expansion mutation causing Huntington’s disease (HD) is highly correlated 
with the rate of pathogenesis leading to disease onset considerable variance in age-at-onset remains 
unexplained. Therefore, other factors must influence the pathogenic process. We asked whether 
these factors were related to natural biological variation in the sensory-motor system. 
In 243 participants (96 premanifest and 35 manifest HD; 112 controls) sensory-motor structural MRI, 
tractography, resting-state fMRI, electrophysiology (including SEP amplitudes), motor score ratings, 
and grip force as sensory-motor performance were measured. Following individual modality analyses 
we used principal component analysis (PCA) to identify patterns associated with sensory-motor 
performance, and manifest versus premanifest HD discrimination. 
We did not detect longitudinal differences over 12 months. PCA showed a pattern of loss of caudate, 
grey and white matter volume, cortical thickness in premotor and sensory cortex, and disturbed 
diffusivity in sensory-motor white matter tracts that was connected to CAG repeat-length. Two 
further major principal components appeared in controls and HD individuals indicating that they 
represent natural biological variation unconnected to the HD mutation. One of these components did 
not influence HD while the other non-CAG driven component of axial versus radial diffusivity contrast 
in white matter tracts were associated with sensory-motor performance and manifest HD.  
The first component reflects the expected CAG expansion effects on HD pathogenesis. One non-CAG 
driven component reveals an independent influence on pathogenesis of biological variation in white 
matter tracts and merits further investigation to delineate the underlying mechanism and the 
potential it offers for disease modification.   
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Introduction 
In Huntington’s disease (HD), the length of the expanded CAG tract in HTT explains about half of the 
variability of motor age-at-onset and is therefore the main determinant of biological events prior to 
clinical diagnosis (GeM-HD Consortium, 2015). The remaining variability is independent of CAG 
repeat length and reflects the modifying influence of genetic and environmental factors on the 
pathogenic process (GeM-HD Consortium, 2015). Structural differences in cerebral white and grey 
matter may be detectable as far as 15-20 years before onset of unequivocal signs of HD and have 
been reported using VBM  and DTI  (for a review see (Georgiou-Karistianis, et al., 2013); Thieben et 
al., 2002; Aylward, 2007; Rosas et al., 2008). Similar to structural abnormalities, cross-sectional task-
based, or resting state functional MRI (fMRI) studies have documented widespread cortical and 
subcortical changes of brain function in manifest HD (Wolf, et al., 2014). TRACK-HD, a large 
longitudinal study combining clinical and structural imaging data from both premanifest and early 
manifest HD participants showed that clinical measures, e.g. motor and cognitive tasks, and 
volumetric imaging tracked disease evolution were associated with manifest HD . PREDICT-HD, a 
longitudinal study in premanifest HD (preHD), demonstrated that motor and cognitive task 
performance, and structural imaging (in particular putamen volume), improved predictions of motor 
diagnosis compared with models using HTT CAG repeat length and age .  
Some of the effects reported in TRACK-HD and PREDICT-HD were independent of HTT CAG repeat 
length and age. This indicates that biological variation exists that is not related to the cause of HD but 
may be common in the population and, when present in an individual with the HTT CAG-repeat 
expansion, exerts an influence on HD pathogenesis. The identification of such traits could help reveal 
an interaction between the biology underlying the biological trait and the pathogenesis or 
manifestation of HD. The trait itself or the genetics underlying its variation could suggest a route to 
disease modification (genetic or pharmaceutical). Thus, HD-independent work on mechanisms 
underlying the trait could provide specific pathways/processes to be tested as candidates for HD 
modification. It remains unresolved which additional biological factors are associated with task 
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performance and clinical disease stage. We addressed this question in an a priori defined neuronal 
network. We focused on sensory-motor circuits that involve brain areas for which macro- 
(volumetric) and microstructural (DTI) abnormalities have consistently been reported in HD. These 
include cortical somatosensory projections, abnormal in manifest disease  the primary sensory 
cortex, in which there is evidence of thinning prior to symptom onset, white matter changes assessed 
using DTI, and SEPs where amplitudes of cortical components were reduced.  
Most previous analyses – including analyses of the Track-HD data – have examined these measures 
one at a time. The fact that differences to controls are expected for many of these in HD is a premise 
of the present study in which we investigate the patterns by which they differ. Analysing data from 
different modalities one at a time does not reveal these patterns. We aimed to first describe patterns 
of the HTT CAG-repeat expansion associated pathology of the sensory-motor circuit using multimodal 
measurements, i.e. sensory-motor network brain structure (VBM, sensory-motor cortex thickness 
and DTI tractography), function (functional MRI and electrophysiology), and sensory-motor task 
performance (grip force and motor score). We hypothesized that non-CAG-repeat driven factors 
influence the pathogenic process and thus predict task performance and clinical disease stage and 
examined whether these factors were related to natural biological variation in the sensory-motor 
system.  
 
Methods 
We investigated sensory-motor clinical measures, and used neuroimaging and electrophysiological 
techniques to investigate macrostructure, microstructure and network function. Following 
independent single modality evaluation, we employed principal component analysis (PCA) as a 
descriptive tool to identify data patterns using multimodal assessments. Finally, we asked whether 
those PCA patterns (1) were associated with pathology that is also known to be linked to HTT CAG-
repeat expansion,   (2) were able to discriminate between controls, preHD and early HD participants, 
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and  (3) were associated with clinical measures of sensory-motor network performance (grip force 
and UHDRS motor score). 
 
Participants 
All individuals who met baseline eligibility criteria for the TRACK-HD premanifest cohort in 2008 (for 
inclusion/exclusion criteria see (Tabrizi et al., 2009) were eligible to participate in Track-On regardless 
of current disease status. A premanifest gene carrier was either (a) an existing premanifest gene 
carrier previously enrolled in TRACK-HD or ( b) a newly recruited premanifest gene carrier with CAG 
repeat length ≥ 40 and burden of pathology score (CAG-35.5) × age >250. All participants had to be 
able to tolerate MRI, and sample donation, and control participants were age and gender frequency 
matched to the premanifest gene carrier group. 
Participants were assessed at baseline and 12-months at four study sites in London (61 participants; 
25.1%), Paris (64; 26.3%), Leiden (60; 24.7%) and Vancouver (58; 23.9%). The study was approved by 
local ethical committees, and written informed consent was obtained from each participant.  
The United Huntington’s Disease Rating Scale (UHDRS) motor part was administered at both visits. 
Participants with a UHDRS diagnostic confidence score of 4 on the motor scale (criteria for clinical 
diagnosis of early HD) at 12-months were defined as the early (diagnosed) group. The remaining HD 
group was divided into preHD-A (further from predicted diagnosis age; ≥10.8 years at baseline) and 
preHD-B (nearer; < 10.8 years) based on the survival analysis formula .  
 
Clinical assessment and electrophysiology 
Participants were assessed clinically, including grip force analysis (Reilmann, et al., 2010), and HTT 
CAG repeat length determined as described for the TRACK-HD study . At all four sites somatosensory 
evoked potentials (SEP) were recorded following median nerve stimulation with surface electrodes, 
and at three sites transcranial magnetic stimulation (TMS) was done as previously described using 
established techniques . The protocol included M. abductor pollicis brevis (APB) hot-spot and motor 
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threshold determination, motor evoked potential latencies and amplitudes, input/output curves at 
rest (110%, 130%, 150% resting motor threshold) and with pre-activation (125%, 150%, 175% active 
motor threshold), and silent period determination.  
 
Neuroimaging 
Voxel based morphometry 
Voxel based morphometry data were acquired using previously validated protocols for multi-site use  
on two different 3T MRI scanner systems (Philips Achieva at Leiden and Vancouver and Siemens TIM 
Trio at London and Paris). Cortical thickness measures were generated for each participant using 
Freesurfer version 5.3.0 applying default parameters and optimized for 3T data (Fischl and Dale, 
2000). Measures were extracted from Brodmann areas: BA4a/4b (motor cortex, M1); BA6 (premotor 
cortex, PMC) and BA3a/3b, BA1, BA2 (somatosensory cortex, S1) 
https://surfer.nmr.mgh.harvard.edu/fswiki/BrodmannAreaMaps. All segmentations were visually 
inspected for accuracy, blind to participant status.  
 
Diffusion tensor imaging 
Diffusion-weighted images with 42 unique gradient directions (b = 1000 sec/mm
2
) were acquired 
from both Siemens and Phillips scanners. Eight images with no diffusion weighting (b = 0 sec/mm
2
) 
and one image with no diffusion weighting (b = 0 sec/mm
2
) were acquired from the Siemens and 
Philips scanners respectively. For the Siemens scanners, TE = 88ms and TR = 13s; for the Phillips 
scanners, TE = 56ms and TR = 11s. Voxel size for the Siemens scanners was 2 x 2 x 2 mm and for the 
Phillips scanners 1.96 x 1.96 x 2. 75 slices were collected for each diffusion-weighted and non-
diffusion weighted volume. The diffusion data were preprocessed using standard FSL pipelines . Data 
were corrected for eddy current distortions, diffusion tensors fitted using DTFIT and all metrics 
derived.  
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For DTI, the no-gradient (B0) image was then skull-stripped using the Brain Extraction Tool (BET) and 
was manually examined and corrected. (For Siemens data B0 images were merged to create a mean). 
Diffusion tensors were then fit to the corrected data using dtifit. FA, AD and RD values were derived 
from the tensors. For registration, we first created a high quality T1 brain mask by combining and 
dilating a thresholded segmented image (created using the VBM toolbox http://www.neuro.uni-
jena.de/vbm/) with an eroded T1 mask from BET. The mask was then applied to the original, brain-
extracted, T1 image.  The resultant T1 image was then registered to the B0 image using FLIRT 
(Jenkinson and Smith, 2001). Within-voxel crossing fibers were modelled using a Bayesian 
probabilistic method implemented in Bedpostx (Behrens, et al., 2007). 
For fiber-tracking, pathways selected were between S1 and somatosensory thalamus; M1 and motor 
thalamus; PMC and the motor thalamus and the corticospinal tract (CST), connecting M1 and the 
cerebral peduncle. For all regions except the cerebral peduncle, we used a regions of interest (ROI) 
approach. The main advantage in using a single voxel is that the signal measured fully represents 
the activity or structure within that voxel and is not impacted by the signal in neighboring voxels. 
However, it is widely accepted that neighbouring voxels are likely to have a similar signal, be it 
resting state activity or white matter microstructure. In fact, averaging over a ROI can significantly 
increase the signal to noise ratio (SNR) compared to that of a single voxel. A single voxel, for 
example, may be heavily impacted by the presence of other tissues or non-neuronal noise which 
would lower the SNR and the quality of the extracted signal. The location of a single voxel can also 
vary considerably between individuals. Using a cluster of voxels rather than an individual voxel 
within a region would provide greater confidence that the 'nodes' used in the analyses were 
located in the anatomical or functional region of interest.  Furthermore, when defining a 'node' 
based on the literature or a previous study, it is possible to use both standardised atlases or masks 
to create a ROI. This ensures across-participant consistency in terms of location. It is important to 
note, however, that for instance for DTI, effects can be masked or diluted by reverse-sense 
changes in different voxels within a single ROI. There is evidence that, for example, FA can increase 
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in some voxels due to selective degradation of one of two fibre populations, but decreases due to 
the same effect in neighbouring voxels that contain only one fibre population (Groeschel et al, 
2014). In averaging over a ROI it is, therefore, possible to mix voxels with differing effects, which 
may be partially cancelled out on averaging. Finally, for DCM (see below) the timeseries extraction 
was based on a principal components approach. Instead of signal averaging, we therefore 
extracted the signal that explains the majority of the variance in that ROI. For the tractography 
analyses, all metrics are weighted to ensure that those streamlines or fibres which contribute most 
towards the formation of a tract are most represented. 
ROI were created using the Anatomy Toolbox; thalamic regions for DTI and DCM analyses were 
therefore identical. The cortical regions were, however, different from those used in the DCM 
analyses as larger regions were more suitable for fibre-tracking. The cerebral peduncle region was 
created using the FSL Montreal Neurological Institute template and the Johns Hopkins University 
White Matter Labels atlas. All regions were defined in standard space and warped into native space 
for each participant using the inverse deformation parameters that were outputted from the DARTEL 
registration for the resting state fMRI images (see resting state fMRI methods section). Masks were 
used to exclude any streamlines that tracked via the contralateral hemisphere or posteriorly to the 
thalamus and peduncle and to ensure tracts did not extend beyond the white matter into grey 
matter, CSF or dura.  
For each participant, and each set of tracts, probabilistic tractography was then performed using 
probtrackx. Connectivity distributions were generated from our seed regions in native space. The 
resulting tract images were then warped into diffusion space using the FLIRT tool and overlayed onto 
the B0 image for quality checking. FA, AD and RD values were extracted for each participant for each 
tract.    
Resting state functional MRI 
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Resting-state fMRI data were collected using 48 continuously acquired ascending axial slices covering 
the whole cortex and cerebellum (slice thickness: 2.8 mm, gap: 1.5 mm, in plane resolution 3.3 x 3.3 
mm, field of view (FOV) 212 mm) with a T2*-weighted echo-planar imaging (EPI) sequence 
(repetition time (TR) 3000 ms, echo time (TE) 30 ms, flip angle (FA) 80°). 165 volumes were acquired 
in a single 8:20 min run. Preprocessing and subsequent statistical analyses were performed using 
SPM8 (Wellcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm). Dynamic Causal 
Modelling (DCM) using a stochastic framework, which models the randomness inherent within 
resting state brain activity  was then employed to investigate causal interactions between five 
regions within the sensorimotor network. Model specification and estimation were conducted using 
DCM10 (SPM12bWellcome Trust Centre for Neuroimaging) and all connectivity parameters extracted 
for further analysis.  
For resting state fMRI, the first four EPI images were discarded to allow for steady state equilibrium. 
The T1 scan was segmented into grey and white matter using the VBM8 toolbox 
(http://dbm.neuro.uni-jena.de/vbm/) and deformation parameters extracted using DARTEL  
(Ashburner, 2007). The segmented images were used to create an improved anatomical scan for co-
registration. Functional images were first realigned and field maps used for inhomogeneity 
correction. EPI images were then co-registered to the new anatomical image and normalised using 
the DARTEL deformation parameters. Finally the data were smoothed using a 6mm full-width at half-
maximum Gaussian kernel. Using a first level design consisting of smoothed images only, the 
principal eigenvariate of the white matter and CSF time series were extracted from a single voxel 
located within the pons (0, -24, -33) or lateral ventricle  (-1, 45, 3) respectively. The white matter and 
CSF signals were then included with movement regressors as nuisance covariates in a second GLM at 
the individual level. The timeseries for each region within our model was then extracted using this 
GLM.  The model consisted of five regions within the sensory and motor networks within the left 
hemisphere (dominant). Cortical regions were derived using co-ordinates from previous Track-HD 
studies: S1 (-40, -34, 61); M1 (-40, -18, 60); and the PMC (-24, 0, 54). For the thalamic regions, see 
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DTI methods.  For cortical regions, timeseries were extracted by placing an 8mm sphere around the 
specified co-ordinates, localized to the nearest local maximum for peak activity, within a regional 
anatomical mask generated by either the WFUPickatlas (Eickhoff, et al., 2005) or the Anatomy 
Toolbox (Maldjian, et al., 2003).  For the thalamic regions of interest, the principal eigenvariate of the 
timeseries was extracted from the pre-defined mask. Connections between and within all regions 
were modelled except the bidirectional connections between the two thalamic regions, the cortical 
motor regions and the sensory thalamic region and the S1 and the motor thalamic composite region; 
this totalled 17 connections. DCM specification and estimation was carried out with DCM10 in SPM 
software (SPM12b; Wellc me Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) and 
connectivity parameters for each participant were extracted. The DCM estimation and model 
convergence were examined using SPM-derived quality assurance.  
 
Statistical analysis 
We first inspected all data for implausible outliers (between 0 and 2% of data, depending on the 
measure), which were either corrected or discarded after joint review with the subject-matter 
investigators. We used log or square root transforms when appropriate to achieve approximate 
residual normality, as is assumed by inference procedures.  
For modeling group differences in outcomes among early HD, preHD-B, preHD-A, and controls, we 
used general weighted least square (GWLS) regression with restricted maximum likelihood 
estimation (Diggle, et al., 1994). The method accounts for repeated measure correlations among 
participants with measures at two visits. Participants with only one observation were also included 
however. This increases statistical power and ensures unbiased longitudinal analyses if visit 2 data is 
missing at random.  
Individual measures from the various modalities were treated, one-at-a-time, as outcome variables. 
The main effects of interest were the above HD groups and their potential interaction with time 
between visits ("time"). Longitudinal group effects were tested via the time interactions with group.  
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The "cross-sectional" effects of interest were mean group values, averaged over both visits. These 
were estimated by a linear combination of main effects of group and group-by-time interaction, such 
that estimated baseline and 12 month values were given equal weight. These averaged cross-
sectional comparisons reduce statistical noise due to factors such as measurement error and 
accurate but irrelevant measurement of short term (e.g. day-to-day) fluctuations, leading to smaller 
standard errors for group comparisons. 
Because we also attempted to measure longitudinal change over 1 year, one might question the 
validity of using both the baseline and follow-up measures for a mean cross-sectional analysis.   The 
justification is empirical and due to the slow evolution of most HD phenomenon. Even for measures 
that exhibit statistically significant longitudinal changes over one year, the magnitude of change is 
quite small in comparison to the cross sectional changes exhibited between HD groups and controls.  
This cross sectional difference is the net result of many years of longitudinal change (Tabrizi et al., 
2009; Tabrizi et al., 2013). We also note that this is an observational study. Within the broad ranges 
defined by our groupings, the time of the baseline measurement is arbitrary. For measures that are 
not subject to practice effects, there is no reason to prefer time 1 or time 2 as representative of 
premanifest or control states.   
We controlled for age at study entry, gender, study site (scanner) and education level, as well as their 
interaction with time. For TMS thresholds, we additionally controlled for main effects of skull to 
cortex (M1) distance and for Freesurfer measures of mean cortical thickness in the left Brodmann 
areas B4a and B4b (the cortical areas stimulated). Some models also controlled for underlying HD 
progression risk determined by CAG repeat length and age via the cumulative probability of onset 
(CPO) statistic from a survival analysis of onset ages . Because variance of outcome measures 
sometimes changes notably in early HD vs preHD vs controls, separate residual covariance was 
estimated for each group. We used the Kenward-Rogers correction to estimate denominator degrees 
of freedom (Kenward and Roger, 1997). All models were fit using Proc Mixed from SAS 9.4 (Littell, et 
al., 2006). Within modalities (electrophysiology, DTI, DCM, etc.) we also calculated false discovery 
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rates (FDR), abbreviated by q, using the Benjamini and Hochberg method (Benjamini and Hochberg, 
1995).  
We created a composite grip force motor score from the sum of sample-standardized orientation 
and position indices, collected while grip force heavy-load task was performed with the dominant 
hand. 
For the final steps of the statistical regression analyses, which involved composite scores created 
from multiple variables, we addressed the issue of missing data by use of multiple imputation 
(Schafer, 1997) done separately for cases and controls. MI was based on outcome measures at 
baseline and follow-up (treated as separate variables) along with all demographic covariates, 
including HD group and study site interactions with time. Five imputations were generated using Proc 
MI and subsequent model inferences were adjusted using Proc MIAnalyze (SAS 9.4). 
Principal component analysis (PCA) was performed on outcome variables of interest as identified by 
their between-group differences in the GWLS regressions. The PCA input was the maximum 
likelihood estimate of the correlation matrix, derived during the multiple imputation procedure. Non-
rotated component scores were then used in to model the relationships to grip force, UHDRS motor 
score (Pearson correlations and linear models), and manifest versus premanifest HD discrimination 
(logistic discrimination).  
For the PCA, we selected measures from each of the modalities. We were guided by the results of 
individual modality analyses, i.e. we chose measures with the greatest difference between controls 
and HD. Some of the measures within a given modality were highly correlated, for instance the DTI 
measures from all tracts or cortical thickness from all regions. Hence we only included for instance 
diffusivity measures from 2 of the 4 tracts in the multi-model PCA. Overall, we included only 15 
variables within the multimodal PCA to ensure representation of the different modalities was roughly 
equal. We included VBM data (volumes of white matter, grey matter, and caudate), cortical thickness 
data (BA6 (premotor cortex), BA3a+2 (somatosensory cortex)), diffusion metrics from tractography 
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(AD and RD of S1-thalamus and PMC-thalamus tracts), effective connectivity parameters from DCM 
(PMC-thalamus and PMC- PMC connections), and SEPs (N20/P25 amplitude and N20 latency) into the 
PCA (multimodal-PCA). In a second PCA that focused solely on DTI, we included RD and AD measures 
from all 4 available DTI tracts. We were interested in the question of whether patterns in HD 
participants differed from those in controls or were similar. For this reason, we did the PCAs 
separately in HD and healthy controls.  
 
Results 
The total Track-On cohort comprised 131 HD (101 former TRACK-HD and 30 new premanifest) and 
112 controls (79 former TRACK-HD and 33 new) recruited between April 16, 2012 and December 10, 
2012 (Table 1). At the 12-month follow-up visit, 11 participants from the HD group and 7 from the 
control group did not take part. The most common reasons for withdrawal were intolerance to MRI, 
personal time constraints and the burden of the study day.  
We defined a priori a total of 53 measures for analysis (17 DCM, 3 brain volume, 7 cortical thickness, 
12 DTI, 14 electrophysiology; supplementary table 1). First we asked if there was detectable change 
in any of the measures from baseline to the 12 month visit. Longitudinal change was small and not 
statistically significant (data not shown). In contrast, cross-sectional differences among the groups, 
averaged over time, were evident and are presented in table 2.  
PCA was performed on all gene-carrier participants (combined HD and preHD), and, independently, 
in controls because we were interested in comparing independently derived descriptive patterns 
between the HD and the control groups.  
In the combined HD group, multimodal-PCA reduced the dimensionality of the data to three 
important dimensions or principal components (PCs) based on their eigenvalues (Table 2; 
supplementary table 2). In HD, the first multimodal-PC explained 21% of the variance in the data. In 
the multimodal-PC1 dimension, lower caudate, grey and white matter volumes, and lower BA6 and 
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BA1 and 2 cortical thickness, were associated with higher AD and RD of S1-thalamus and PMC-
thalamus tracts (Fig 1A). The first PC was the only multimodal-PC that correlated significantly with 
the age-CAG cumulative probability of onset (r=-0.58, p<0.0001, Fig 1B). Further, this first 
multimodal-PC showed association with sensory-motor network specific performance (grip force 
orientation and position index; Fig 1C, Table 3). Multimodal-PC1 substantially mediated, and 
improved upon, the predictive effect of age-CAG on grip force (p=0.006) such that there was no 
residual association of age-CAG (p=0.468) after this PC was included in the model. Multimodal-PC1 
was also associated with clinical motor score (p=0.041), and probability of manifest versus preHD 
status (p=0.003, Fig 1D, Table 3). However, unlike for grip force associations, the influence of age-
CAG on clinical motor score or HD status remained significant, though weaker, when the first PC was 
included in the model. This indicates that the first multimodal-PC does not completely mediate the 
age-CAG relationship to motor score.  
The second multimodal-PC in HD explained 15% of data variance (Fig 1A). Higher AD was correlated 
with smaller SEP amplitudes and greater cortical thickness. Multimodal-PC2 was not predicted by age 
and CAG length (r=0.12, p=0.178), nor was it associated with HD outcomes (data not shown). This 
second PC may represent an element of biological variation unrelated to HD, an interpretation 
supported by partial similarity to the first multimodal-PC in an independent PCA in healthy controls. 
The patterns were similar except that volumes of grey and white matter and caudate also correlated 
with the component in controls but not HD (Fig 1A; supplementary table 3). Consistent with their 
known central role in the illness, these volumes instead contributed substantially to the first principal 
component of variation among the HD groups.   
The third multimodal-PC in HD, explaining 11% of data variance, revealed a dimension of contrast 
between AD and RD (Fig 1A). The third PC was a substantial additional predictor of grip force score 
(p=0.036), of UHDRS motor score (p=0.007) and of diagnosis (p=0.021, Fig 1E, Table 3). Caudate, grey, 
and white matter volumes contributed very little to this third multimodal-PC, and its values were not 
predicted by age and CAG length (r=0.04; p=0.643). By definition, this AD versus RD component is 
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uncorrelated with the more general brain structural effects of the first multimodal-PC, which are 
driven by genetic HD load. Furthermore, multimodal-PCA of the normal controls revealed a similar 
AD versus RD contrasting component that accounted for 12 % of the variance within the control 
group (supplementary table 3). Therefore, higher AD compared to RD is associated with HD 
pathogenesis in the presence of a CAG expansion mutation, but is also observed as natural variation 
in healthy controls. It is independent of the unique HD brain structural effects that are related to HTT 
CAG repeat-length.  
We then asked if the relationship of AD and RD extended to the other white matter tracts that we 
had measured but excluded from the initial PCA. There was a very high correlation of AD, and RD, 
values among the four tracts. The finding was consistent in separate analyses of the controls (Figs 2A, 
B) and the HD group (Figs 2D, E). This was further reflected in a PCA restricted to AD and RD values 
from all 4 tracts (ADRD-PCA) and performed independently in healthy controls and HD participants. 
Two dimensions (illustrated for controls in Fig 2C and for HD in Fig 2F) explained 94% of the 
variability in controls and 90% of variability in HD participants (Fig 2G). ADRD-PC1 contains a 
dimension of common correlation among all diffusivity measures while ADRD-PC2, consistent with 
the multimodal PCA, reflects the contrast between AD and RD values (Fig 2G, Table 4). AD measures 
were significantly correlated with grip force, but the RD measures were not (Fig 2H, Table 5). There 
was no correlation between age and grip force performance in controls, and correlation of AD and 
RD with grip force was not significantly affected if controlled for age. In HD participants, the patterns 
were similar to controls. The correlation of both ADRD-PC1 and AD with grip force was stronger, and 
the relationship of ADRD-PC2 and grip force was slightly stronger than in controls (Fig 2I, Table 5). 
 
Discussion 
In this study, we went beyond the analysis of data from single modalities one at a time to investigate 
data patterns reflecting the structural and functional state of an a priori defined sensory-motor 
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circuit that is relevant for motor control. We aimed to delineate CAG repeat length dependent and 
independent patterns that influence the pathogenic process before disease onset. We did not detect 
longitudinal differences over 12 months. Cross-sectionally, in HD, dimension reduction using principal 
component analyses revealed one dimension specific to its cause, i.e. HTT CAG repeat-length 
expansion, that included a correlated loss of caudate, grey and white matter volume, cortical 
thickness, and disturbed diffusivity in white matter tracts. Within our data, this component predicted 
sensory-motor performance and a diagnosis of manifest HD. Two further dimensions were not 
unique to HD but were also present in controls. The first of these dimension represented natural 
variation in axonal diffusivity, cortical thickness and SEP amplitude but did not influence HD. The 
second non-CAG dimension consisting of an AD versus RD contrast in white matter tracts did 
influence HD in that it was an additional predictor of sensory-motor performance in HD and controls, 
and a clinical diagnosis of HD. This pattern of diffusivity is consistent with naturally occurring 
variability in a biological trait that influences HD manifestations.  
The HTT mutation is the main determinant of pathogenesis that leads to the structural and functional 
neurodegeneration that underlies HD and the emergenc  of unequivocal clinical signs. We examined 
this pathogenic process in that we investigated the structural and functional state in an a priori 
defined sensory-motor circuit relevant for motor control. Presumably owing to the slow progression 
of HD and perhaps also the sensitivity limits of the methods employed, there was no detectable 
change in any of the sensory-motor modalities within the 12-month observation period. This may 
appear inconsistent with the findings in the original TRACK-HD study at 12 months (Tabrizi et al., 
2011). It is important to note, though, that many of the measures that we used in the present study 
were not part of TRACK-HD. It is therefore possible that e.g. electrophysiological measures or DTI are 
less suitable for the detection of change over 12 months either because network brain function, or 
white matter microstructure, do not change much or because measurement error for these 
measures is large relative to the change that happens. In addition, in TRACK-HD most detectable 
changes were observed only in the diagnosed, early HD group, which was both substantially larger 
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and more advanced in disease than in our newly diagnosed HD subgroup. It is therefore conceivable 
that the ability to detect change over time depends on the measurements themselves,  on the time 
that elapsed between measurements, and also on the stage of HD. Cross-sectionally however, our 
data confirmed that, compared with controls, in HTT gene expansion carriers white and grey matter 
brain structure is diminished, and sensory afferent signal transmission is concomitantly slower and 
less efficient. Furthermore, these differences were measurable before unequivocal motor signs of HD 
emerged. Brain structure and electrophysiology remained abnormal following the emergence of 
diagnostic motor signs. Further, in early HD, in addition to RD, AD was substantially worse and 
effective connectivity from PMC to thalamus reduced. The analyses used to examine differences at 
the individual modality level the patterns by which the data differ across modalities. We therefore 
next employed multivariate analysis using PCA to reveal such data patterns. PCA reduced data to two 
dimensions that were relevant for HD and one that represents natural variation that does not 
influence HD. The first dimension relevant to HD contained a correlated loss of caudate, grey and 
white matter volume, cortical thickness, and disturbed diffusivity in white matter tracts. These 
changes increased with an increase of the age-CAG-length HD risk, indicating that structural 
abnormalities relate to the primary cause of pathogenesis. For performance that is related to the 
sensory-motor network, we show that the current structure of white and grey matter within the 
network is a more relevant (and presumably more proximal) predictor than the key HD biological 
variables, age and CAG-repeat length. Our data indicate that structural changes in white and grey 
matter are relevant for sensory-motor task performance and are an integral part of HD biology. 
We then examined whether we could identify biological variation that was independent of genetic 
risk but still associated with sensory-motor performance and clinical category, i.e. preHD versus 
manifest HD. PCA identified two dimensions not connected to CAG-repeat length in which data 
variance was similar in controls and HD participants. One of these dimensions was not associated 
with clinical status. It contrasted more AD with smaller SEP amplitudes and greater cortical thickness, 
and, in controls, increased grey matter volume as well. In HD participants this dimension was not 
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related to age-CAG repeat length. The dimension seems to capture an element of natural biological 
variation unrelated to HD.  
Axonal damage is known to be associated with a loss of amplitude of evoked potentials so that it is 
conceivable that variation of axonal microstructure relates to SEP amplitude. In addition, the 
distance between the soma of the cell receiving sensory afferent inputs within S1 and the recording 
electrode on the scalp can also influence SEP amplitude. With a thicker cortex that distance may be 
slightly greater, and subsequently the SEP amplitude smaller.  
A second dimension unrelated to age-CAG repeat length in both controls and HD participants 
revealed differences between AD and RD in white matter tracts. This dimension was also, by 
definition, uncorrelated with either the previous non-CAG-repeat dimension or with the primary 
dimension related to CAG-repeat length found only in HD. This axial-radial DTI dimension was 
independently associated with sensory-motor performance and a clinical diagnosis of HD. Somewhat 
surprisingly, it was also associated with task performance in controls. The diffusivity contrast was 
evident in all the tracts we analysed, and, thus, is not specific to a single white matter tract. 
Therefore, the diffusivity patterns constitute a quantitative phenotype that reflects naturally 
occurring variability in white matter tract biology. AD reflects water movement in tracts parallel to 
the main fiber organization while RD measures water movement perpendicular to this organisation.  
 
In animal models there is evidence suggesting that AD reflects axonal integrity and RD myelin 
integrity. Myelin-producing glial cells and neurons form a unit in which axon integrity depends on 
intact myelin and axons help maintain that myelin. In diseases primarily affecting white matter 
myelin, such as multiple sclerosis, clinical signs seem to manifest when axonal damage arises from 
the loss of myelin trophic support (Nave, 2010). Naturally occurring variability in the axon-myelin unit 
in itself does not cause disease. However, with a genetically sensitized background such as in HD or 
in other diseases naturally occurring variability in the make-up of the axon-myelin unit may influence 
onset and the course of the disease. DTI diffusivity patterns need to be interpreted with caution, as 
we cannot infer with confidence the anatomical significance based on the diffusivity changes we 
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observed in our participants. Nonetheless, given the prominent involvement of white matter in HD , 
and since mutant huntingtin has been implicated in oligodendrocyte function and axonal transport , 
our observational data suggest that it is worth exploring the role of the differential loss of myelin and 
axons in HD pathogenesis further.  
In contrast to brain structure, sensory-motor functional measures such as effective connectivity or 
SEPs did not contribute significantly to models of clinical status. While some functional measures 
differed significantly between preHD or early HD versus controls, task performance or clinical status. 
One possible explanation could be the use of resting state measures. Brain activity differs 
substantially when performing a task compared to when at rest even within our carefully chosen 
sensory-motor network model. It is also possible that the precision of functional measurements is 
inadequate to reliably detect relevant underlying phenomena. 
In summary, we went beyond the analysis of single modality data one at a time to assess patterns of 
structural and functional properties of the sensory-motor system in HD and healthy controls using 
multivariate analysis. While there was very little, if any, change in these modalities over 12 months, 
the cross-sectional analysis revealed a dimension of white and grey matter loss attributable to HD 
biology that is associated with network specific task performance and clinical diagnosis. Our data 
suggest that the microstructural anatomy influencing water diffusivity perpendicular to white matter 
tracts, e.g. myelin, is already changed in preHD. In contrast, the anatomical compartment that 
determines water diffusivity parallel to the tracts, e.g. the axon, is not substantially affected until 
early HD. Although these patterns are amplified with HD, we also show that these measures of white 
matter organization consistently vary among healthy controls across different white matter tracts. 
Given the absence of an age-CAG correlation, this indicates that naturally occurring variability in 
white matter tract microanatomy may represent a biological trait with a disease modifying influence 
on the pathogenesis of HD. These findings need to be confirmed, e.g. examining more tracts with DTI 
in conjunction with more task performance outcomes.  
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No disease modifying treatment is known that can delay the onset or slow the progression of HD, 
although there are several promising approaches about to reach clinical testing (Wild and Tabrizi, 
2014). These approaches directly target the production or regulation of the huntingtin protein. 
However, there is still a need to identify other important disease-modifying biological factors in HD 
as these may eventually provide additional drug development targets for this devastating disease 
(GeM-HD Consortium, 2015).  
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Tables 
Table 1: Demographic and clinical characteristics of study participants by subgroup. Disease burden 
was calculated as age X (CAGn – 35.5). Education was classified according to the International 
Standard Classification of Education (ISCED). Data are given as means (SD). 
Table 2: Principal component analysis with data from all modalities. In independent analyses, in HD 
participants and healthy controls the first 3 principal components (PC) explain about 50% of the 
variance.  
Table 3: PCA (on data from all modalities) association with grip force position and orientation 
composite score, UHDRS motor score and diagnosis status, i.e. premanifest versus manifest 
Huntington’s disease. Abbreviations. ln(OR) = natural log of odds ratio; CPO = cumulative probability 
of onset based on age and CAG length CPO mediated (%) = 1 – (t value of CPO in CPO-only model/ 
CPO t value in multivariate model); (a) per 10% increase in CPO; for diagnosis state log odds ratio per 
10% increase in CPO (b) PC coefficients are per standard deviation. 
Table 4: Correlations of observed axial and radial diffusivity in independent PCAs in controls and 
Huntington’s disease participants.  
Table 5: Correlations of grip force with axial (AD) and radial diffusivity (RD) in independent principal 
component analyses (PCAs) in controls and Huntington’s disease participants. Abbreviations: CST: 
cortico-spinal tract. M1: motor cortex. S1: somatosensory cortex. PMC: premotor cortex. 
Supplementary Table 1: Individual modality results of variables included in principle component 
analysis. There is significant global white and grey matter loss across all clinical HD groups, but most 
pronounced in the early HD group. Cortical thickness in regions that are important in sensory-motor 
integration circuits was similar for preHD-A and controls. However, both the PMC (BA6) and S1 (BA2, 
BA3a) were significantly thinner in preB and in early HD than in controls. In all tracts FA, AD and RD 
were similar in the preHD-A group and controls. In preHD-B, RD, but not AD, was significantly 
increased in all four tracts. In the early HD group, in all four tracts RD and AD were greater than in 
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controls. Effective connectivity from PMC to motor thalamus was significantly reduced in the early 
HD group. SEP N20 latencies and N20/P25 amplitudes of somatosensory evoked potentials were 
abnormal in preHD and manifest HD. The early HD group had a much higher position-index and a 
higher orientation index in grip force experiments. 
Data are means of visit 1 and visit 2 data (95% CI) or estimates of the differences between the means 
of visit 1 and visit 2 data in HD groups and controls (95% CI; p value; q value). All estimates are 
adjusted for age, sex, and study site. Abbreviations. WM: white matter; GM: grey matter; FA: 
Fractional Anisotropy; RD: Radial Diffusivity; AD: Axial Diffusivity; q results from corrections for 
multiple comparisons using false positive discovery rates. 
§
Volumes are relative to total intracranial 
volume. * in mm
2
 s
-1
 10
-3
; sqr: square root.  
Supplementary Table 2: Principal Component (PC) Analysis correlations of the observed variables 
from all modalities with PCs in Huntington’s disease participants. Correlations of a magnitude greater 
than 0.400 are highlighted in bold. Abbreviations: M1: motor cortex; S1: somatosensory cortex; PMC: 
pre-motor cortex. GM: grey matter. WM: white matter. AD: axial diffusivity. RD: radial diffusivity. 
Supplementary Table 3: Principal Component (PC) Analysis correlations of the observed variables 
from all modalities with PCs in control participants. Correlations of a magnitude greater than 0.400 
are highlighted in bold. Abbreviations: M1: motor cortex; S1: somatosensory cortex; PMC: pre-motor 
cortex. GM: grey matter. WM: white matter. AD: axial diffusivity. RD: radial diffusivity. 
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Figure legends 
Figure 1. Multimodal principal component analysis. A. Heat map of correlation coefficients of each 
modality with dimensions derived from principal component analysis done independently in healthy 
controls and HD participants. The first multimodal principal component (PC) in HD contains higher 
axial (AD) and radial diffusivity (RD) in S1-Thalamus (Thal) and PMC-Thalamus tracts; less cortical 
thickness in the PMC (BA6) and S1 (BA3a; BA2); and less total brain grey matter (GM), white matter 
(WM) and caudate volume. Multimodal-PC3 in HD reflects the difference between axial and radial 
diffusivity. Multimodal-PC2 in HD and PC1 in controls show a similar pattern of thicker cortex, higher 
axial diffusivity and lower SEP amplitudes. B. HD multimodal-PC1 scores negatively correlate with 
cumulative probability of onset (CPO) and grip force orientation and position index (C; pre HD blue 
dots, manifest HD red dots). D. Multimodal-PC1 scores distinguish manifest HD (red dots) from 
preHD participants (blue dots; the Y-axis just separates HD and controls). E. Multimodal-PC3 is a 
substantial additional predictor of manifest HD (p=0.021) improving the separation of manifest HD 
(red dots) and preHD participants (blue dots). Abbreviations: PMC-ThM: effective connectivity PMC 
to motor thalamus parcellation; PMC-PMC: effective connectivity PMC to PMC; S1-M1: effective 
connectivity S1 to motor cortex. 
Figure 2. Principal component analysis with axial and radial diffusivity (ADRD-PCA). In controls, 
axial diffusivity values (A), or radial diffusivity values (B), from different tracts are highly correlated. 
C. ADRD principal component (PC) 1 reflects that greater, or smaller, axial diffusivity is associated 
with greater, or smaller, radial diffusivity. There is additional variability in the relationship of axial 
and radial diffusivity, which is reflected in ADRD-PC2. In HD participants, the relationship between 
axial diffusivity (AD) (D), or radial diffusivity (RD) (E), in the two tracts is similar to controls. F. 
Manifest HD participants (red dots) have higher than average axial and radial diffusivity values and 
higher axial relative to radial diffusivity values (grey triangle) than preHD (blue dots). G. A principal 
component analysis with axial and radial diffusivity values from all 4 tracts done independently in 
healthy controls and HD participants reveals that PC1 and PC2 explain 94% of data variability in 
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controls and 90% in HD participants. Heat maps of correlation coefficients show that in controls and 
HD participants in PC1 axial and radial diffusivity are positively correlated while PC2 reflects the 
difference between axial and radial diffusivity. In controls (H) and HD participants (I) higher axial 
diffusivity is associated with higher grip force orientation and position index scores. NB. C and F 
contain approximate representations of the PCs relative to paired, observed AD and RD measures. 
Abbreviations: M1: motor cortex; S1: somatosensory cortex; CST: cortico-spinal tract; PMC: pre-
motor cortex. 
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Variable Control 
N=112 
preHD A 
N=41 
preHD B 
N=55 
preHD all 
N=96 
Early HD 
N=35 
Gender N (%F) 67 (59.8) 24 (58.5) 26 (47.3) 50 (52.1) 19 (54.3) 
Age 48.1 (10.7) 40.4 (8.8) 44.0 (9.0) 42.4 (9.0) 45.3 (8.4) 
Education 3.9 (1.0) 4.0 (1.0) 4.0 (1.0) 4.0 (1.0) 3.9 (0.9) 
CAG Repeat Length -- 42.3 (2.2) 43.4 (2.3) 42.9 (2.3) 43.5 (2.5) 
Disease burden -- 257.2 (30.7) 330.0 (39.8) 298.9 (51.1) 348.2 (61.6) 
Motorscore 1.3 (1.6) 5.4 (3.3) 5.0 (3.8) 5.2 (3.6) 12.6 (7.1) 
 
Table 1. Demographic and clinical characteristics of study participants by subgroup.  
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 Controls preHD-A versus controls preHD-B versus controls Early HD versus controls 
Brain volume (VBM)     
Caudate
§
 0.5155 (0.5049 to 
0.5261) 
-0.05 (-0.07 to -0.04; p<0.0001; 
q<0.0001) 
-0.10 (-0.12 to -0.08; p<0.0001; 
q<0.0001) 
-0.15 (-0.17 to -0.13; p<0.0001; 
q<0.0001)  
White matter
§
 0.3176 (0.3128 to 
0.3224) 
-0.01 (-0.02 to -0.0003; p=0.04; 
q=0.07) 
-0.01 (-0.02 to -0.003; p=0.004; 
q=0.006) 
-0.02( -0.03 to -0.01; p<0.0001; 
q<0.0001) 
Grey matter
§
 0.4512 (0.4443 to 
0.4581) 
-0.01 (-0.02 to 0.0001; p=0.05; 
q=0.07)  
-0.01 (-0.02 to -0.003; p=0.01; 
q=0.01) 
-0.03 (-0.04 to -0.01; p<0.0001; 
q<0.0001) 
Cortical thickness (mm)     
Premotor cortex (BA6) 2.6852 (2.6590 to 
2.7114) 
0.001 (-0.05 to 0.05; p=0.97; 
q=0.97) 
-0.08 (-0.12 to -0.04; p<0.0001; 
q=0.0003) 
0.09 (-0.14 to -0.05; p<0.0001; 
q=0.0006) 
Somatosensory cortex (BA2) 2.2353 (2.2099 to 
2.2607) 
0.01 (-0.04 to 0.05; p=0.72; 
q=0.97) 
-0.04 (-0.07 to -0.01; p=0.02; 
q=0.04) 
-0.06 (-0.11 to -0.01; p=0.02; 
q=0.03) 
Somatosensory cortex (BA3a)  1.6850 (1.6598 to 
1.7102) 
-0.03 (-0.07 to 0.01; p=0.17; 
q=0.97) 
-0.04 (-0.07 to -0.009; p=0.01; 
q=0.04) 
-0.07 (-0.11 to -0.03; p=0.0006; 
q=0.002) 
Somatosensory cortex (BA1) 2.3187 (2.2852 to 
2.3522) 
-0.00269 (-0.05110 to 0.04572; 
p=0.9122; q=0.9723) 
0.02364 (-0.1051 to -0.01144; 
p=0.0152; q=0.0354) 
-0.07925 (-0.1543 to -0.00420; 
p=0.039; q=0.0545) 
Somatosensory cortex (BA2) 2.2353 (2.2099 to 
2.2607) 
0.008070 (-0.03636 to 0.05250; 
p=0.7180; q=0.9723) 
-0.04265 (-0.07976 to -0.00554; 
p=0.0247; q=0.0433) 
-0.06331 (-0.1143 to -0.01234; 
p=0.016; q=0.0279) 
Motor cortex (BA4a) 2.6629 (2.6244 to 
2.7014) 
0.01463 (-0.05047 to 0.07972; 
p=0.6557; q=0.9723) 
-0.02544 (-0.07921 to 0.02833; 
p=0.3506; q=0.4090) 
-0.08815 (-0.1535 to -0.02284; 
p=0.009; q=0.0210) 
Motor cortex (BA4b) 2.4495 (2.4052 to 
2.4938) 
0.03572 (-0.03568 to 0.1071; 
p=0.3224; q=0.9723) 
0.04015 (-0.01765 to 0.09794; 
p=0.1718; q=0.2405) 
-0.00184 (-0.07559 to 0.07192; 
p=0.96; q=0.96) 
DTI tractography      
Motor cortex – motor 
thalamus 
FA 0.4757 (0.4694 to 
0.4820) 
-0.01 (-0.02 to 0.002; p=0.11; 
q=0.22) 
-0.01 (-0.02 to -0.003; p=0.01; 
q=0.02) 
-0.00036 (-0.01 to 0.01; p=0.95; 
q=0.95) 
RD* 0.511 (0.506 to 0.517) 0.0011 (0.0028 to 0.02; p=0.01; 
q=0.11) 
0.019 (0.010 to 0.027; p=0.0001; 
q=0.0001) 
0.017 (0.007 to 0.026; p=0.001; 
q=0.002) 
AD* 0.713 (0.708 to 0.717) 0.021 (-0.01 to 0.016; p=0.11; 
q=0.22) 
0.011 (-0.028 to 0.025; p=0.12; 
q=0.13) 
0.033 (0.018 to 0.048; p<0.0001; 
q=0.0002) 
Premotor cortex – motor 
thalamus  
FA 0.4923 (0.4856 to 
0.4990) 
-0.01 (-0.02 to 0.002; p=0.10; 
q=0.22) 
-0.01 (-0.02 to -0.002; p=0.02; 
q=0.04) 
-0.00285 (-0.01467 to 0.008970; 
p=0.63; q=0.71) 
RD* 0.494 (0.488 to 0.499) 0.010 (0.0016 to 0.019; p=0.02; 
q=0.11) 
0.017 (0.0086 to 0.026; p=0.0001; 
q=0.0004) 
0.018 (0.0084 to 0.028; 
p=0.0006; q=0.001) 
AD* 1.121 (1.112 to 1.131) -0.0015 (-0.02 to 0.013; p=0.80; 
q=0.89) 
0.0089 (-0.005 to 0.023; p=0.21: 
q=0.21) 
0.032 (0.015 to 0.048; p=0.0003; 
q=0.0008) 
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 Somatosensory cortex – 
Sensory thalamus 
FA 0.4784 (0.4725 to 
0.4843) 
-0.005 (-0.02 to 0.006; p=0.35; 
q=0.5) 
-0.01 (-0.02 to 0.00001; p=0.05; 
q=0.06) 
0.003064 (-0.00682 to 0.01294; 
p=0.53; q=0.66) 
RD* 0.517 (0.511 to 0.522) 0.0082 (-0.001 to 0.017; p=0.08; 
q=0.22) 
0.018 (0.0096 to 0.026; p=0.0001; 
q=0.0001) 
0.014 (0.005 to 0.023; p=0.003; 
q=0.004) 
AD* 1.140 (1.131 to 1.149) 0.0048 (-0.0018 to 0.018; 
p=0.46; q=0.57) 
0.016 (0.0015 to 0.030; p=0.03; 
q=0.04) 
0.036 (0.021 to 0.052; p<0.0001; 
q<0.0001) 
 Cortico-spinal tract FA 0.5254 (0.5200 to 
0.5308) 
-0.004 (-0.01 to 0.005; p=0.39; 
q=0.52) 
-0.01 (-0.02 to -0.001; p=0.04; 
q=0.05) 
0.002152 (-0.00797 to 0.01227; 
p=0.67; q=0.71 
RD* 0.479 (0.474 to 0.484) 0.0055 (-0.0025 to 0.014; 
p=0.17; q=0.31) 
0.015 (0.0074 to 0.023; p=0.0002; 
q=0.0004) 
0.013 (0.0038 to 0.022; p=0.006; 
q=0.008) 
AD* 1.175 (1.167 to 1.184) 0.000086 (-0.01 to 0.01; p=0.99; 
q=0.99) 
0.010 (0.0028 to 0.024; p=0.1219; 
q=0.13) 
0.034 (0.019 to 0.050; p<0.0001; 
q=0.0002) 
Dynamic causal modelling     
Premotor cortex – Motor thalamus 0.1853 (0.1470 to 
0.2237) 
-0.04206 (-0.1015 to 0.01743; 
p=0.1631; q=0.6930) 
-0.06057 (-0.1239 to 0.002718; 
p=0.0604; q=0.5137) 
-0.09966 (-0.1542 to -0.04507; 
p=0.0005; q=0.0093) 
Premotor cortex self-connection -0.03134 (-0.03444 to -
0.02823) 
-0.00374 (-0.00855 to 0.001060; 
p=0.1246; q=0.6930) 
-0.00828 (-0.01657 to 0.000006208; 
p=0.0502; q=0.5137) 
-0.00818 (-0.01465 to -0.00170; 
p=0.0145; q=0.1227) 
Electrophysiology     
SEP N20 latency (ms) 
19.81 (19.60 to 20.01) 0.02 (-0.33 to 0.38; p=0.89; 
q=0.94) 0.54 (0.15 to 0.93; p=0.007; q=0.04) 
0.70 (0.23 to 1.16; p=0.004; 
q=0.04) 
SEP N20/P25 amplitude (sqr mV) 
1.87 (0.66 to 3.09) 0.07 (-0.13 to 0.27; p=0.46; 
q=0.84) 
-0.31 (-0.48 to -0.14; p=0.0006; 
q=0.01) 
-0.27 (-0.43 to -0.11; p=0.001; 
q=0.03) 
Grip force     
Orientation index (log) 
1.46 (1.39 to 1.54) 0.09 (-0.03416 to 0.21; p=0.15; 
q=0.27) 
0.06 (-0.05711 to 0.18; p=0.31; 
q=0.31) 
0.49 (0.3394 to 0.65; p<0.0001; 
q<0.0001) 
Position index (log) 
0.47 (0.40 to 0.54) 0.07 (-0.05639 to 0.19; p=0.27; 
q=0.27) 
0.10 (-0.00314 to 0.20; p=0.057; 
q=0.17 
0.58 (0.4269 to 0.73; p<0.0001; 
q<0.0001 
Composite index (log) 
1.93 (1.80 to 2.07) 0.16 (-0.08384 to 0.40; p=0.20; 
q=0.27) 
0.16 (-0.05186 to 0.37; p=0.14; 
q=0.21) 
1.07 (0.7757 to 1.37; p<0.0001; 
q<0.0001 
Supplementary Table 1. Individual modality results of variables included in principle component analysis.
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HD 
Controls 
PC Eigenvalue %variance 
explained 
cumulative Eigenvalue %variance 
explained 
cumulative 
1 3.102 20.7 20.7 3.432 22.9 22.9 
2 2.267 15.1 35.8 2.353 15.7 38.6 
3 1.703 11.3 47.1 1.850 12.3 50.9 
4 1.442 9.7 56.8 1.103 7.4 58.2 
5 1.084 7.2 64.0 1.081 7.2 65.5 
6 0.995 6.6 70.6 0.968 6.5 71.9 
7 0.891 6.0 76.6 0.901 6.0 77.9 
8 0.795 5.3 81.9 0.829 5.5 83.4 
9 0.704 4.7 86.6 0.706 4.7 88.2 
10 0.531 3.5 90.1 0.581 3.9 92.0 
11 0.522 3.5 93.6 0.446 3.0 95.0 
12 0.468 3.1 96.7 0.335 2.2 97.2 
13 0.211 1.4 98.1 0.229 1.5 98.8 
14 0.161 1.1 99.2 0.128 0.9 99.6 
15 0.125 0.8 100 0.059 0.4 100 
Table 2: Principal component analysis with data from all modalities. 
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 Regression 
coefficient 
Standard 
error 
T value CPO 
mediated (%) 
p 
Grip force 
CPO only (a)      
Intercept -0.3831 0.1560 -2.46  0.015 
CPO (a) -0.1462 0.0498 2.93  0.004 
PC1 added      
Intercept -0.1156 0.1812 -0.64  0.525 
CPO (a) -0.0442 0.0606 0.73 75.1 0.468 
PC1 (b) -0.1742 0.0614 -2.84  0.006 
PC3 added      
Intercept -0.0939 0.1767 -0.53  0.596 
CPO (a) -0.0357 0.0602 0.59 79.9 0.555 
PC1 -0.1805 0.0617 -2.93  0.005 
PC3 -0.1519 0.0700 -2.17  0.036 
UHDRS motor score 
CPO only (a)      
Intercept 1.853 0.154 12.02  <.0001 
CPO (a) -0.273 0.049 5.55  <.0001 
PC1 added      
Intercept 2.043 0.178 11.46  <.0001 
CPO (a) -0.201 0.060 3.35 39.6 0.001 
PC1 (b) -0.124 0.060 -2.06  0.041 
PC3 added      
Intercept 2.068 0.173 11.95  <.0001 
CPO (a) -0.191 0.059 3.25 41.4 0.002 
PC1 -0.131 0.058 -2.24  0.027 
PC3 -0.180 0.065 -2.77  0.007 
Premanifest versus manifest Huntington’s disease 
CPO only (a) ln(OR)     
 0.679 0.147 4.61  <.0001 
PC1 added      
CPO (a) 0.422 0.172 2.54 44.9 0.011 
PC1 (b) 0.627 0.211 2.98  0.003 
PC3 added      
CPO (a) 0.444 0.172 2.58 44.0 0.010 
PC1 0.653 0.206 3.17  0.002 
PC3 0.496 0.214 2.32  0.021 
 
Table 3: PCA (on data from all modalities) multivariate model  of grip force position and orientation 
composite score, UHDRS motor score and diagnosis status, i.e. premanifest versus manifest 
Huntington’s disease.  
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Variable Controls Huntington’s Disease 
 PC1 PC2 PC1 PC2 
M1 – Thal  AD 0.785 -0.598 0.793 -0.577 
S1 – Thal  AD 0.812 -0.531 0.784 -0.548 
CST AD  0.797 -0.544 0.782 -0.542 
PMC – Thal  AD 0.747 -0.625 0.770 -0.581 
M1 – Thal  RD 0.749 0.631 0.706 0.666 
S1 – Thal   RD 0.770 0.562 0.626 0.662 
CST RD  0.741 0.595 0.644 0.702 
PMC – Thal RD 0.634 0.718 0.619 0.684 
 
Table 4: Correlations of observed axial and radial diffusivity in independent PCAs in controls 
and Huntington’s disease participants.  
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Grip force correlation Controls Huntington 
 Correlation 
coefficient 
p Correlation 
coefficient 
p 
PCA1 mean 0.273 0.0065 0.381 <.0001 
PCA2 mean -0.168 0.0978 -0.201 0.0352 
M1 – Thalamus  AD 0.342 0.0006 0.420 <.0001 
S1 – Thalamus  AD 0.338 0.0007 0.407 <.0001 
CST AD 0.277 0.0058 0.408 <.0001 
PMC – Thalamus AD 0.291 0.0036 0.410 <.0001 
M1 – Thalamus  RD 0.087 0.3946 0.136 0.1577 
S1 – Thalamus  RD 0.136 0.1825 0.077 0.422 
CST RD 0.070 0.4921 0.127 0.1857 
PMC – Thalamus RD 0.075 0.4629 0.103 0.2864 
 
Table 5: Correlations of grip force with axial (AD) and radial diffusivity (RD) in independent principal 
component analyses (PCAs) in controls and Huntington’s disease participants. 
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 PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 PC12 PC13 PC14 PC15 
SEP 
amplitude 
0·242 -0·412 -0·282 0·185 0·100 0·174 0·552 -0·426 0·266 -0·055 0·225 0·073 0·039 0·027 -0·007 
SEP latency -0·228 0·077 -0·154 0·166 0·645 0·575 -0·139 0·196 -0·129 0·182 0·141 0·128 0·013 -0·004 -0·015 
PMC – 
Thalamus  
0·334 0·126 0·389 -0·505 -0·040 -0·017 0·151 0·402 0·431 0·169 0·180 0·176 0·019 0·015 0·038 
PMC – PMC  0·240 0·280 0·039 -0·591 0·344 0·116 0·437 -0·064 -0·168 0·029 -0·323 -0·226 0·026 -0·030 0·018 
S1 - M1  -0·229 0·149 -0·111 0·178 -0·589 0·637 0·144 0·156 0·112 0·008 -0·262 0·007 0·028 0·037 0·003 
S1 – 
Thalamus AD 
-0·450 0·630 -0·439 0·080 -0·014 -0·238 0·205 0·101 0·120 0·062 0·001 0·083 0·012 -0·169 -0·195 
PMC–
Thalamus AD 
-0·398 0·588 -0·513 0·214 0·079 -0·235 0·142 0·134 0·075 0·041 0·064 -0·119 -0·016 0·148 0·199 
PMC–
Thalamus RD 
-0·460 0·326 0·649 0·165 -0·048 0·032 0·271 -0·155 -0·143 0·109 0·081 0·065 -0·299 0·031 -0·010 
S1 – 
Thalamus RD 
-0·406 0·277 0·701 0·358 0·081 -0·084 0·129 -0·048 -0·038 -0·024 0·007 -0·015 0·323 0·027 -0·002 
BA6 
thickness 
0·732 0·554 -0·027 0·015 -0·021 0·039 -0·155 -0·134 0·022 0·098 0·055 -0·106 0·009 0·242 -0·168 
BA3a 
thickness 
0·532 0·592 -0·067 -0·023 -0·016 -0·002 -0·084 -0·260 -0·117 -0·083 -0·143 0·483 0·029 -0·039 0·096 
BA2 
thickness 
0·578 0·564 0·139 0·170 -0·085 0·234 -0·127 -0·076 0·085 -0·103 0·252 -0·299 -0·021 -0·200 0·071 
GM volume 0·577 -0·200 -0·140 0·172 -0·300 -0·112 0·257 0·178 -0·466 0·364 0·148 0·014 0·064 -0·040 0·019 
WM volume 0·471 -0·174 0·126 0·571 0·222 -0·150 -0·051 -0·016 0·318 0·313 -0·352 -0·045 -0·058 -0·054 0·023 
Caudate 
volume 
0·570 -0·049 0·082 0·389 0·169 -0·060 0·255 0·456 -0·093 -0·435 -0·049 0·050 -0·069 0·033 -0·041 
 
Supplementary Table 2: Principal Component (PC) Analysis correlations of the observed variables from all modalities with PCs in Huntington’s disease participants. 
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 PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 PC12 PC13 PC14 PC15 
SEP amplitude -0531 0080 -0012 0251 -0130 0547 0390 0023 0297 0127 0172 0206 -0059 0022 0001 
SEP latency -0304 -0011 -0018 -0367 0283 0495 -0453 0490 -0039 -0001 0008 -0025 -0003 0015 -0006 
PMC – 
Thalamus  
0352 -0077 0459 -0524 0186 -0205 0269 0088 -0112 0388 0226 0118 -0010 -0008 -0001 
PMC – PMC  0204 0255 0122 0086 0619 0400 0065 -0509 -0228 0042 -0044 -0091 -0005 -0017 0001 
S1 - M1  0315 0070 -0124 0403 0534 -0177 0349 0480 -0038 -0194 0072 -0002 0068 0018 0012 
S1 – Thalamus 
AD 
0321 0765 -0434 -0167 -0049 0029 0086 0049 0147 0063 -0039 -0004 0112 -0166 -0125 
PMC–
Thalamus AD 
0291 0712 -0499 -0201 -0049 -0002 0103 0038 0094 0177 -0146 -0070 -0022 0148 0126 
PMC–
Thalamus RD 
0223 0498 0734 0153 -0226 0126 -0056 0132 -0028 -0053 -0039 -0009 0080 -0164 0116 
S1 – Thalamus 
RD 
0289 0647 0600 0115 -0165 0021 -0031 0088 -0128 -0097 -0066 0037 -0111 0179 -0107 
BA6 thickness 0854 -0182 -0173 -0073 -0066 0124 0068 0069 0043 -0139 0047 -0064 -0369 -0096 0011 
BA3a 
thickness 
0715 -0204 -0132 0156 -0323 0255 -0043 0013 -0118 0082 0347 -0254 0157 0065 -0012 
BA2 thickness 0778 -0094 -0245 -0101 -0050 0123 -0152 -0118 -0134 -0227 0021 0422 0110 0030 0026 
GM volume 0435 -0595 0045 0109 -0138 0231 0228 0177 -0132 0254 -0448 0001 0059 -0005 -0028 
WM volume 0452 -0271 0400 -0299 0146 0066 0091 -0106 0590 -0223 -0077 -0096 0104 0058 -0007 
Caudate 
volume 
0483 -0004 0043 0463 0217 -0145 -0483 -0008 0322 0369 0017 0088 -0042 0000 -0006 
 
Supplementary Table 3: Principal Component (PC) Analysis correlations of the observed variables from all modalities with PCs in control participants.  
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Figure 1. Multimodal principal component analysis. A. Heat map of correlation coefficients of each modality 
with dimensions derived from principal component analysis done independently in healthy controls and HD 
participants. The first multimodal principal component (PC) in HD contains higher axial (AD) and radial 
diffusivity (RD) in S1-Thalamus (Thal) and PMC-Thalamus tracts; less cortical thickness in the PMC (BA6) 
and S1 (BA3a; BA2); and less total brain grey matter (GM), white matter (WM) and caudate volume. 
Multimodal-PC3 in HD reflects the difference between axial and radial diffusivity. Multimodal-PC2 in HD and 
PC1 in controls show a similar pattern of thicker cortex, higher axial diffusivity and lower SEP amplitudes. B. 
HD multimodal-PC1 scores negatively correlate with cumulative probability of onset (CPO) and grip force 
orientation and position index (C; pre HD blue dots, manifest HD red dots). D. Multimodal-PC1 scores 
distinguish manifest HD (red dots) from preHD participants (blue dots; the Y-axis just separates HD and 
controls). E. Multimodal-PC3 is a substantial additional predictor of manifest HD (p=0.021) improving the 
separation of manifest HD (red dots) and preHD participants (blue dots). Abbreviations: PMC-ThM: effective 
connectivity PMC to motor thalamus parcellation; PMC-PMC: effective connectivity PMC to PMC; S1-M1: 
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effective connectivity S1 to motor cortex.  
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Principal component analysis with axial and radial diffusivity (ADRD-PCA). In controls, axial diffusivity values 
(A), or radial diffusivity values (B), from different tracts are highly correlated. C. ADRD principal component 
(PC) 1 reflects that greater, or smaller, axial diffusivity is associated with greater, or smaller, radial 
diffusivity. There is additional variability in the relationship of axial and radial diffusivity, which is reflected in 
ADRD-PC2. In HD participants, the relationship between axial diffusivity (AD) (D), or radial diffusivity (RD) 
(E), in the two tracts is similar to controls. F. Manifest HD participants (red dots) have higher than average 
axial and radial diffusivity values and higher axial relative to radial diffusivity values (grey triangle) than 
preHD (blue dots). G. A principal component analysis with axial and radial diffusivity values from all 4 tracts 
done independently in healthy controls and HD participants reveals that PC1 and PC2 explain 94% of data 
variability in controls and 90% in HD participants. Heat maps of correlation coefficients show that in controls 
and HD participants in PC1 axial and radial diffusivity are positively correlated while PC2 reflects the 
difference between axial and radial diffusivity. In controls (H) and HD participants (I) higher axial diffusivity 
is associated with higher grip force orientation and position index scores. NB. C and F contain approximate 
representations of the PCs relative to paired, observed AD and RD measures. Abbreviations: M1: motor 
cortex; S1: somatosensory cortex; CST: cortico-spinal tract; PMC: pre-motor cortex.  
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